Tonix Pharmaceuticals Holding Corp., of New York, said that following a meeting with the FDA in March regarding TNX-102 SL (cyclobenzaprine), the company's phase III post-traumatic stress disorder treatment candidate, the agency confirmed that a single-study new drug application (NDA) approval could be possible.